In the past two decades, several molecular targeted inhibitors have been developed and
evaluated clinically to improve the survival of patients with cancer. Molecular targeted …

Tyrosine kinase inhibitors (TKIs)-treatments bring significant benefit for patients harboring
epidermal growth factor receptor (EGFR) mutations, especially for those with lung cancer …

BACKGROUND The LH surge induces great physiological changes within the preovulatory
follicle, which culminate in the ovulation of a mature oocyte that is capable of supporting …

Aptamer-related technologies represent a revolutionary advancement in the capacity to
rapidly develop new classes of targeting ligands. Structurally distinct RNA and DNA …

ERBB family members including epidermal growth factor receptor (EGFR) also known as
HER1, ERBB2/HER2/Neu, ERBB3/HER3 and ERBB4/HER4 are aberrantly activated in …

A series of novel compounds carrying 1, 2, 4-triazole scaffold were prepared and evaluated
for their antiproliferative activities against NCI 60 cell line. Compounds 10 (a, c), 11 (ad), and …

Human epidermal growth factor receptor (HER) 2 (HER2) is overexpressed in 20–30% of
breast cancers. HER2 is a preferred target for treating HER2-positive breast cancer …

Mucins are large glycoproteins that are ubiquitous in the animal kingdom. Mucins coat the
surfaces of many cell types and can be secreted to form mucus gels that assume important …

The receptor tyrosine kinase HER2 is overexpressed in approximately 20% of breast cancer,
and its amplification is associated with reduced survival. Trastuzumab emtansine (Kadcyla …

Chronic kidney disease (CKD) is characterized by persistent inflammation and progressive
fibrosis, ultimately leading to end‐stage renal disease. Although many studies have …